Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood ...

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

"These results suggest that anti-obesity medication use, with relatively safe, effective, and sustainable weight loss, may be ...

American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic anterior optic neuropathy (NAION).

From lemon coffee to oatzempic, there's always a new weight loss hack people are buzzing about. The latest of these is ...

Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of its $3.1 billion takeover of Carmot Therapeutics as it tries to catch up with the leaders in the fast ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple oral and poster presentations, ...